Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19

2020 | journal article. A publication with affiliation to the University of Göttingen.

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19​
Hoffmann, M.; Schroeder, S.; Kleine-Weber, H.; Müller, M. A.; Drosten, C. & Pöhlmann, S. ​ (2020) 
Antimicrobial Agents and Chemotherapy, 64(6).​ DOI: https://doi.org/10.1128/AAC.00754-20 

Copy

Further links

Documents & Media

License

GRO License GRO License

Details

Authors
Hoffmann, Markus; Schroeder, Simon; Kleine-Weber, Hannah; Müller, Marcel A.; Drosten, Christian; Pöhlmann, Stefan 
Issue Date
2020
Journal
Antimicrobial Agents and Chemotherapy 
ISSN
0066-4804
eISSN
1098-6596
Language
English

Export Metadata

Refman EndNote BibTeX RefWorks Excel CSV

Reference

Citations


Social Media